Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov enrollment closed later-stage tilt small index

Moderate Chronic Plaque Psoriasis: later-stage trial registry

A small indexed set (1 trial) with no open enrollment listed right now.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · none currently recruiting · #11,370 of 28,707 conditions by registered trial count

Moderate Chronic Plaque Psoriasis: 1 US clinical trial tracked, none currently recruiting.

Moderate Chronic Plaque Psoriasis is the subject of 1 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 1 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is UCB Biopharma SRL, running 1 of these trials.

Enrollment posture brief

Registry condition moderate-chronic-plaque-psoriasis

OPEN 0 | RECR 0% | LATE 1 | EARLY 0 | RANK #11370 | SPON 1

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Moderate Chronic Plaque (th…0%
Open-enrollment share among volume-matched conditions near Moderate Chronic Plaque Psoriasis

Moderate Chronic Plaque Psoriasis has no open enrollment in this registry pull (1 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Moderate Chronic Plaque Psoriasis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Moderate Chronic Plaque Psoriasis is recruiting below its size-band peers.

    0 of 1 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 31

Phase Distribution

PhaseTrial count
Phase 3 1

Top Sponsors

Named interventions

Most-linked intervention names on Moderate Chronic Plaque Psoriasis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Certolizumab pegol Drug
1 trials
Placebo Drug
1 trials

US sites by state

Facility locations filed on Moderate Chronic Plaque Psoriasis trials. A trial with sites in several states counts in each.

Texas 1 trials
Michigan 1 trials
Kansas 1 trials
Illinois 1 trials
Georgia 1 trials
Florida 1 trials
California 1 trials
Arizona 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Moderate Chronic Plaque Psoriasis page

1 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • No Moderate Chronic Plaque Psoriasis trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • UCB Biopharma SRL sponsors the most Moderate Chronic Plaque Psoriasis trials on record, review their full trial history before evaluating a specific study. See UCB Biopharma SRL's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Moderate Chronic Plaque Psoriasis condition card totals 1 registered trials; most-linked intervention Certolizumab pegol; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.